CoChat

Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs

Open access

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Abstract

Mood disorders (depression, bipolar disorders) are prevalent and disabling. They are also highly co-morbid with other psychiatric disorders. Currently there are no objective measures, such as blood tests, used in clinical practice, and available treatments do not work in everybody. The development of blood tests, as well as matching of patients with existing and new treatments, in a precise, personalized and preventive fashion, would make a significant difference at an individual and societal level. Early pilot studies by us to discover blood biomarkers for mood state were promising [1], and validated by others [2]. Recent work by us has identified blood gene expression biomarkers that track suicidality, a tragic behavioral outcome of mood disorders, using powerful longitudinal within-subject designs, validated them in suicide completers, and tested them in independent cohorts for ability to assess state (suicidal ideation), and ability to predict trait (future hospitalizations for suicidality) [3–6]. These studies showed good reproducibility with subsequent independent genetic studies [7]. More recently, we have conducted such studies also for pain [8], for stress disorders [9], and for memory/Alzheimer’s Disease [10]. We endeavored to use a similar comprehensive approach to identify more definitive biomarkers for mood disorders, that are transdiagnostic, by studying mood in psychiatric disorders patients. First, we used a longitudinal within-subject design and whole-genome gene expression approach to discover biomarkers which track mood state in subjects who had diametric changes in mood state from low to high, from visit to visit, as measured by a simple visual analog scale that we had previously developed (SMS-7). Second, we prioritized these biomarkers using a convergent functional genomics (CFG) approach encompassing in a comprehensive fashion prior published evidence in the field. Third, we validated the biomarkers in an independent cohort of subjects with clinically severe depression (as measured by Hamilton Depression Scale, (HAMD)) and with clinically severe mania (as measured by the Young Mania Rating Scale (YMRS)). Adding the scores from the first three steps into an overall convergent functional evidence (CFE) score, we ended up with 26 top candidate blood gene expression biomarkers that had a CFE score as good as or better than SLC6A4, an empirical finding which we used as a de facto positive control and cutoff. Notably, there was among them an enrichment in genes involved in circadian mechanisms. We further analyzed the biological pathways and networks for the top candidate biomarkers, showing that circadian, neurotrophic, and cell differentiation functions are involved, along with serotonergic and glutamatergic signaling, supporting a view of mood as reflecting energy, activity and growth. Fourth, we tested in independent cohorts of psychiatric patients the ability of each of these 26 top candidate biomarkers to assess state (mood (SMS-7), depression (HAMD), mania (YMRS)), and to predict clinical course (future hospitalizations for depression, future hospitalizations for mania). We conducted our analyses across all patients, as well as personalized by gender and diagnosis, showing increased accuracy with the personalized approach, particularly in women. Again, using SLC6A4 as the cutoff, twelve top biomarkers had the strongest overall evidence for tracking and predicting depression after all four steps: NRG1, DOCK10, GLS, PRPS1, TMEM161B, GLO1, FANCF, HNRNPDL, CD47, OLFM1, SMAD7, and SLC6A4. Of them, six had the strongest overall evidence for tracking and predicting both depression and mania, hence bipolar mood disorders. There were also two biomarkers (RLP3 and SLC6A4) with the strongest overall evidence for mania. These panels of biomarkers have practical implications for distinguishing between depression and bipolar disorder. Next, we evaluated the evidence for our top biomarkers being targets of existing psychiatric drugs, which permits matching patients to medications in a targeted fashion, and the measuring of response to treatment. We also used the biomarker signatures to bioinformatically identify new/repurposed candidate drugs. Top drugs of interest as potential new antidepressants were pindolol, ciprofibrate, pioglitazone and adiphenine, as well as the natural compounds asiaticoside and chlorogenic acid. The last 3 had also been identified by our previous suicidality studies. Finally, we provide an example of how a report to doctors would look for a patient with depression, based on the panel of top biomarkers (12 for depression and bipolar, one for mania), with an objective depression score, risk for future depression, and risk for bipolar switching, as well as personalized lists of targeted prioritized existing psychiatric medications and new potential medications. Overall, our studies provide objective assessments, targeted therapeutics, and monitoring of response to treatment, that enable precision medicine for mood disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-021-01061-w

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Steps 1–3: Discovery, Prioritization and Validation of Biomarkers for Mood. A Cohorts used in study, depicting flow of discovery, prioritization, and validation of biomarkers from each step. B Discovery cohort longitudinal within-subject analysis. Phchp### is study ID for each subject. V# denotes visit number. C Differential gene expression in the Discovery cohort- number of genes identified with differential expression (DE) and absent–present (AP) methods with an internal score of 2 and above. Red increased in expression in high mood, blue decreased in expression in high mood. At the discovery step probesets are identified based on their score for tracking mood with a maximum of internal points of 6 (33% (2pt), 50% (4pt) and 80% (6pt)). D Prioritization with CFG for prior evidence of involvement in mood disorders. In the prioritization step probesets are converted to their associated genes using Affymetrix annotation and GeneCards. Genes are prioritized and scored using CFG for mood evidence with a maximum of 12 points. Genes scoring at least 6 points out of a maximum possible of 18 total discovery and prioritization points are carried to the validation step. E Validation in two independent cohort of psychiatric patients with clinically severe depression (HAMD ≥ 22) and clinically severe mania (YMRS ≥ 20). In the validation step biomarkers are assessed for stepwise change from the validation group with mania, to the discovery groups of subjects with high mood, low mood, to the validation group with depression, using ANOVA. N number of testing visits. Two hundred ninety-one biomarkers were nominally significant, and 1446 biomarkers were stepwise changed. PRPS1 and SLC6A4 are examples of significantly increased, respectively, decreased, biomarkers in validation. There were 26 markers that had an overall Convergent Functional Evidence (CFE) score from Steps 1–3 that was at least as good as SLC6A4, which serves as a de facto positive control and that we decided to use as a cutoff. The markers in red are increased in high mood, the markers in blue are decreased in high mood/increased in depression (color figure online).
Fig. 1 Steps 1–3: Discovery, Prioritization and Validation of Biomarkers for Mood. A Cohorts used in study, depicting flow of discovery, prioritization, and validation of biomarkers from each step. B Discovery cohort longitudinal within-subject analysis. Phchp### is study ID for each subject. V# denotes visit number. C Differential gene expression in the Discovery cohort- number of genes identified with differential expression (DE) and absent–present (AP) methods with an internal score of 2 and above. Red increased in expression in high mood, blue decreased in expression in high mood. At the discovery step probesets are identified based on their score for tracking mood with a maximum of internal points of 6 (33% (2pt), 50% (4pt) and 80% (6pt)). D Prioritization with CFG for prior evidence of involvement in mood disorders. In the prioritization step probesets are converted to their associated genes using Affymetrix annotation and GeneCards. Genes are prioritized and scored using CFG for mood evidence with a maximum of 12 points. Genes scoring at least 6 points out of a maximum possible of 18 total discovery and prioritization points are carried to the validation step. E Validation in two independent cohort of psychiatric patients with clinically severe depression (HAMD ≥ 22) and clinically severe mania (YMRS ≥ 20). In the validation step biomarkers are assessed for stepwise change from the validation group with mania, to the discovery groups of subjects with high mood, low mood, to the validation group with depression, using ANOVA. N number of testing visits. Two hundred ninety-one biomarkers were nominally significant, and 1446 biomarkers were stepwise changed. PRPS1 and SLC6A4 are examples of significantly increased, respectively, decreased, biomarkers in validation. There were 26 markers that had an overall Convergent Functional Evidence (CFE) score from Steps 1–3 that was at least as good as SLC6A4, which serves as a de facto positive control and that we decided to use as a cutoff. The markers in red are increased in high mood, the markers in blue are decreased in high mood/increased in depression (color figure online).CC BY · PubMed Central
Fig. 2 Best single biomarkers predictors for depression, state and trait. From top candidate biomarkers after Steps 1–3 (discovery, prioritization, validation-bold) (n = 26). Bar graph shows best predictive biomarkers in each group. All markers are nominally significant p < 0.05. Table underneath the figures displays the actual number of biomarkers for each group whose ROC AUC p values (A–C,) and Cox odds ratio (OR) p values (D) are at least nominally significant. Some gender and diagnosis group are missing from the graph as they did not have any significant biomarkers, or sufficient timepoints in the case of longitudinal predictions. Cross-sectional is based on levels at one visit. Longitudinal is based on levels at multiple visits (integrates levels at most recent visit, maximum levels, slope into most recent visit, and maximum slope). Dividing lines represent the cutoffs for a test performing at chance levels (white), and at the same level as the best biomarkers for all subjects in cross-sectional (gray) and longitudinal (black) based predictions. All biomarkers perform better than chance. Biomarkers performed better when personalized by gender and diagnosis, particularly in females. * survived Bonferroni correction for the number of candidate biomarkers tested (n = 26).
Fig. 2 Best single biomarkers predictors for depression, state and trait. From top candidate biomarkers after Steps 1–3 (discovery, prioritization, validation-bold) (n = 26). Bar graph shows best predictive biomarkers in each group. All markers are nominally significant p < 0.05. Table underneath the figures displays the actual number of biomarkers for each group whose ROC AUC p values (A–C,) and Cox odds ratio (OR) p values (D) are at least nominally significant. Some gender and diagnosis group are missing from the graph as they did not have any significant biomarkers, or sufficient timepoints in the case of longitudinal predictions. Cross-sectional is based on levels at one visit. Longitudinal is based on levels at multiple visits (integrates levels at most recent visit, maximum levels, slope into most recent visit, and maximum slope). Dividing lines represent the cutoffs for a test performing at chance levels (white), and at the same level as the best biomarkers for all subjects in cross-sectional (gray) and longitudinal (black) based predictions. All biomarkers perform better than chance. Biomarkers performed better when personalized by gender and diagnosis, particularly in females. * survived Bonferroni correction for the number of candidate biomarkers tested (n = 26).CC BY · PubMed Central
Fig. 3 Therapeutics: matching with medications. A Pharmacogenomics. See also Tables 3 and S4. B New repurposed drugs using the panels of markers. See also Table 4. There is overlap between depression, bipolar and mania biomarkers. RPL3 could be targeted to treat mania with less risk of inducing depression. Six biomarkers (CD47, FANCF, GLO1, HNRNPDL, OLFM1, SMAD7) could be targeted to treat depression with less risk of inducing mania. Other six biomarkers (DOCK10, GLS, NRG1, PRPS1, TMEM161B, SLC6A4) could be targeted to treat depression fast/powerfully, but may induce mania, so need to be coupled with a mood stabilizer or antipsychotic. An example of the latter is SLC6A4. SSRIs should thus be used cautiously in monotherapy to treat depression, and clinicians should have a low threshold for adding mood stabilizers.
Fig. 3 Therapeutics: matching with medications. A Pharmacogenomics. See also Tables 3 and S4. B New repurposed drugs using the panels of markers. See also Table 4. There is overlap between depression, bipolar and mania biomarkers. RPL3 could be targeted to treat mania with less risk of inducing depression. Six biomarkers (CD47, FANCF, GLO1, HNRNPDL, OLFM1, SMAD7) could be targeted to treat depression with less risk of inducing mania. Other six biomarkers (DOCK10, GLS, NRG1, PRPS1, TMEM161B, SLC6A4) could be targeted to treat depression fast/powerfully, but may induce mania, so need to be coupled with a mood stabilizer or antipsychotic. An example of the latter is SLC6A4. SSRIs should thus be used cautiously in monotherapy to treat depression, and clinicians should have a low threshold for adding mood stabilizers.CC BY · PubMed Central
Fig. 4 Example of report for physicians. Using the panel of the top biomarkers BioM12 + 1: Depression (n = 12 genes), as well as RPL3 for mania risk. This subject (Phchp328) was previously described by us in a suicidality biomarker study (Levey et al. [5]), as high risk for suicide, and died by suicide a year after completing our study. No information was provided to her clinicians by us at that time due to anonymity and privacy rules in research studies. The raw expression values of the biomarkers were Z-scored by gender and diagnosis. The Z-scored expression value of each increased biomarker was compared to the average value for the biomarker in the severely depressed group (HAMD ≥ 22), and the average value of the non-depressed group (HAMD ≤ 7), resulting in scores of 1 or 0, respectively, and 0.5 if it was in between. The reverse was done for decreased biomarkers. The “digitized” biomarkers were then added into a polygenic risk score. The subject had a BioM12 polygenic depression score of 88.46, being at the 90% of the 794 subjects in our database. Three out of the three biomarkers for future risk for depression hospitalizations (NRG1, PRPS1, SMAD7) had a score of 1 in this patient (***). More than 50% of the 6 bipolar biomarkers that are part of the BioM12 (Table 3A and B) (*), as well as the mania marker RPL3 (Table 3C) (*), had a score of 1 in this patient, resulting in increased risk for bipolar switching (**). This subject’s clinical diagnosis was major depressive disorder (MDD), but it is likely she had bipolar disorder. The “digitized” biomarkers were also used for matching with existing psychiatric medications. Biomarkers were matched based on our CFG databases with existing psychiatric medications that had effects on gene expression opposite to depression, in the direction of high mood. Each medication matched to a biomarker got a score of 1 that was then multiplied with the biomarker score of 1, 0.5 or 0. The scores for the medications were added, and medications prioritized by this score. In addition, the signature of the biomarkers in the panel that had a score of 1, and their direction of change, was used to interrogate the CMAP and LINCS databases for new repurposed medications that would treat depression in this patient.
Fig. 4 Example of report for physicians. Using the panel of the top biomarkers BioM12 + 1: Depression (n = 12 genes), as well as RPL3 for mania risk. This subject (Phchp328) was previously described by us in a suicidality biomarker study (Levey et al. [5]), as high risk for suicide, and died by suicide a year after completing our study. No information was provided to her clinicians by us at that time due to anonymity and privacy rules in research studies. The raw expression values of the biomarkers were Z-scored by gender and diagnosis. The Z-scored expression value of each increased biomarker was compared to the average value for the biomarker in the severely depressed group (HAMD ≥ 22), and the average value of the non-depressed group (HAMD ≤ 7), resulting in scores of 1 or 0, respectively, and 0.5 if it was in between. The reverse was done for decreased biomarkers. The “digitized” biomarkers were then added into a polygenic risk score. The subject had a BioM12 polygenic depression score of 88.46, being at the 90% of the 794 subjects in our database. Three out of the three biomarkers for future risk for depression hospitalizations (NRG1, PRPS1, SMAD7) had a score of 1 in this patient (***). More than 50% of the 6 bipolar biomarkers that are part of the BioM12 (Table 3A and B) (*), as well as the mania marker RPL3 (Table 3C) (*), had a score of 1 in this patient, resulting in increased risk for bipolar switching (**). This subject’s clinical diagnosis was major depressive disorder (MDD), but it is likely she had bipolar disorder. The “digitized” biomarkers were also used for matching with existing psychiatric medications. Biomarkers were matched based on our CFG databases with existing psychiatric medications that had effects on gene expression opposite to depression, in the direction of high mood. Each medication matched to a biomarker got a score of 1 that was then multiplied with the biomarker score of 1, 0.5 or 0. The scores for the medications were added, and medications prioritized by this score. In addition, the signature of the biomarkers in the panel that had a score of 1, and their direction of change, was used to interrogate the CMAP and LINCS databases for new repurposed medications that would treat depression in this patient.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 112

Metadata

Authors
Le-Niculescu, H., Roseberry, K., Gill, S. S., Levey, D. F., Phalen, P. L., Mullen, J., Williams, A., Bhairo, S., Voegtline, T., Davis, H., Shekhar, A., Kurian, S. M., & Niculescu, A. B.
Affiliations
  • Indiana University School of Medicine (US)
  • Yale University (US)
  • University of Maryland, Baltimore (US)
  • University of Pittsburgh (US)
  • Scripps Health (US)
Corresponding author
Niculescu, A. B.
Venue
Molecular Psychiatry
Published
2021-04-08
Volume
26
Issue
7
Pages
2776-2804
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3139996120
Cited by
94
References
38
Citations by year
2026: 11 · 2025: 13 · 2024: 18 · 2023: 23 · 2022: 19 · 2021: 10
FWCI
12.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
Funders
  • U.S. Department of Veterans Affairs (I01 CX000139, I01 CX002094)
  • National Institutes of Health (1dp2od007363-01)
  • National Institute of Mental Health (R01MH117431)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
mood disorders, depression, bipolar disorder, circadian genes, serotonin transporter, risk prediction, pharmacogenomics, drug repurposing, suicide risk, transdiagnostic biomarkers, personalized medicine, within-subjects design, circadian rhythm, neuroinflammation
MeSH terms
Humans, Pharmacogenetics, Reproducibility of Results, Risk Assessment, Mood Disorders, Precision Medicine, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. https://app.cochat.ai/papers/10.1038/s41380-021-01061-w
The paper
Le-Niculescu, H., Roseberry, K., Gill, S. S., Levey, D. F., Phalen, P. L., Mullen, J., Williams, A., Bhairo, S., Voegtline, T., Davis, H., Shekhar, A., Kurian, S. M., & Niculescu, A. B. (2021). Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01061-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.